富祥药业(300497) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was CNY 401,061,621.11, representing a 38.23% increase year-over-year[5] - The net profit attributable to shareholders decreased by 93.25% to CNY 587,851.61 for the same period[5] - The net profit after deducting non-recurring gains and losses was CNY -2,600,243.66, a decline of 154.23%[5] - Total revenue for the first nine months of 2022 was CNY 999,139,110.11, an increase of 37.61% compared to CNY 726,088,446.13 in the same period of 2021, primarily due to rising raw material costs and increased costs from new product launches[10] - Net profit attributable to shareholders of the parent company decreased by 71.50% to CNY 45,901,162.55 from CNY 161,074,494.65 year-on-year, mainly due to a decline in total profit[10] - Total profit for the first nine months of 2022 was CNY 43,823,031.50, down 75.58% from CNY 179,452,494.13 in the previous year, attributed to increased raw material prices and higher operating costs[10] - The company reported a net profit of CNY 38,248,045.61 for the period, compared to a net profit of CNY 162,105,922.33 in the same period last year, reflecting a significant decline[22] - The net profit for Q3 2022 was CNY 27,591,333.08, a decrease of 82.4% compared to CNY 156,795,317.53 in Q3 2021[23] - Operating profit for Q3 2022 was CNY 44,797,754.09, down from CNY 180,622,798.01 in the same period last year[23] - The total profit for Q3 2022 was CNY 43,823,031.50, a decline of 75.6% from CNY 179,452,494.13 in Q3 2021[23] Cash Flow and Liquidity - The company's cash flow from operating activities showed a significant decline of 96.37%, amounting to CNY 3,901,885.10[5] - Cash flow from operating activities decreased by 96.37% to CNY 3,901,885.10 from CNY 107,448,534.77, primarily due to increased payments for raw materials[10] - The company’s cash and cash equivalents decreased by 97.81% to -CNY 114,530,977.73 from -CNY 57,900,344.47, reflecting the impact of operating, investing, and financing activities[10] - Cash and cash equivalents at the end of Q3 2022 were CNY 1,069,410,810.42, down from CNY 1,438,855,984.20 at the end of Q3 2021[27] - The company reported a total cash inflow from operating activities of CNY 888,534,437.89 in Q3 2022, compared to CNY 870,729,162.01 in Q3 2021[26] - The net cash flow from investing activities for Q3 2022 was -CNY 440,605,240.03, slightly improved from -CNY 466,084,407.56 in Q3 2021[27] - The company incurred a total cash outflow from financing activities of CNY 827,786,148.91 in Q3 2022, compared to CNY 522,746,615.07 in Q3 2021[27] Assets and Liabilities - The total assets increased by 8.93% to CNY 5,096,103,187.34 compared to the end of the previous year[5] - Inventory increased by 32.24% to CNY 550,318,349.31 due to rising raw material costs and new product launches[9] - Long-term borrowings rose by 182.97% to CNY 998,872,000.00, indicating increased financing activities[9] - Total liabilities rose to CNY 2,218,871,787.29, up 25.6% from CNY 1,767,183,937.38 in the previous period[20] - Non-current assets totaled CNY 2,799,275,991.58, an increase of 18.2% from CNY 2,366,935,280.24 at the beginning of the year[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 29,695, with no preferred shareholders[12] - The largest shareholder, Bao Jianhua, holds 20.88% of the shares, amounting to 114,815,808 shares, with 86,111,856 shares pledged[12] Operational Performance - Total operating revenue for the period reached CNY 1,232,211,008.36, an increase of 15.6% compared to CNY 1,065,981,273.35 in the previous period[22] - Total operating costs amounted to CNY 1,193,962,962.75, up 32.1% from CNY 903,875,351.02 in the prior period[22] - Gross profit margin decreased to approximately 3.1% from the previous period, indicating increased cost pressures[22] - Research and development expenses were CNY 55,798,555.09, representing an increase of 6.3% from CNY 52,296,089.08 in the previous period[22] - The company plans to focus on expanding its market presence and enhancing product development in the upcoming quarters[22] Foreign Exchange Impact - The company reported a significant increase in financial expenses, with a change of -373.87% to -CNY 9,825,215.98, mainly due to increased foreign exchange gains from USD fluctuations[10] - The company experienced a foreign exchange impact of CNY 8,958,526.11 on cash and cash equivalents in Q3 2022[27]